Building ventures and creating value through
Healthy Earth LP (“the “Company”) was founded in late 2013 by Christopher Cogan and the team at Seven Holdings with a goal of becoming the leading sustainable foods company in the United States. Healthy Earth's goal was to aggregating innovative technologies and production methods across the entire spectrum of sustainable foods. The company's mission is to produce the freshest, most nutritious foods possible while also promoting sustainable and, where practical, organic farming best practices. Through expertise in aquaculture, aquaponics, microbiology, feed production and farm management, Healthy Earth develops innovative, commercial-scale operations and alternatives to how sustainable foods are produced and sold.
In 2014 Healthy Earth acquired the aquaculture division of Mote Marine Laboratory which was the second largest producer of sturgeon fish and caviar in the US. In 2015 Healthy Earth acquired Anna Maria Fish company, a producer of sustainably wild-caught mullet and Cortez Botarga, the largest commercial producer of Botarga in the US. Also in 2015, Healthy Earth's mullet operation was selected as a finalist in the international Fish 2.0 competition and won the grand prize in the Blue Economy X-prize competition.
In January 2016, Seven entered into an agreement to sell a majority interest in the Healthy Earth portfolio of companies
Embera NeuroTherapeutics, Inc. is a development stage, pharmaceutical company focused on treating a broad range of addictions and obesity where the major clinical challenge is a limited range of effective drug therapies.
Embera is developing a new drug based on technology developed by Dr. Nick Goeders, Head of the Pharmacology Department at LSUHSC. The company has developed a combination of two existing, FDA-approved drugs. This combination effectively treats addictions with very few side effects. The initial focus will be on cocaine and methamphetamine addiction, but the combination drugs could also be used for alcohol, gambling and other addictions.
Embera NeuroTherapeutics, Inc. has offices in both Shreveport, LA, in alliance with biotechnology initiates in the State of Louisiana , and in the greater Boston area.
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. With technology licensed from Pennington Biomedical Research Center and the LSU Agriculture Center, Esperance is developing a unique, targeted, anticancer fusion protein that is selectively toxic to cancer cells. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.
The company has raised more than $25 million and has recently completed a successful FDA Phase II trial.
in 2015, Esperance partnered with MD Anderson Cancer Center in a deal to accelerate development of the company’s lead anti-cancer drug. Under the agreement , Houston-based MD Anderson will conduct additional studies to help prepare for a Phase III trial of EP-100 in ovarian cancer. EP-100 is Esperance’s lead anti-cancer candidate. The drug targets and destroys cancer cells that produce too much of a certain hormone. Those include breast, prostate, pancreatic, ovarian and testicular cancers.
Jenrin Discovery is a privately-held company headquartered in Westchester, PA. Jenrin is developing a pipeline of proprietary 'first-in-class' small-molecule drugs designed to selectively target peripheral tissues. Many marketed or advanced clinical stage non-psychiatric drugs re plagued by a sub-optimal safety profile, due to psychiatric and neurologic side effects. Jenrin applies its technology and medicinal chemistry expertise to structurally modify such drugs, so as to prevent penetration across the blood-brain barrier, resulting in negligible or no brain levels of drug. The new peripherally selective (PS) chemical entities retain the pharmacological activity and other essential properties of the original parent drug, but carry little or no risk of neuropsychiatric effects, thus offering a safer alternative to the original parents drugs.
Cogan Realty, LLC is a boutique firm investing in select real estate properties throughout Florida and the southeast US. The form also advises high net-worth individuals, institutions and corporations on real estate investment, site selection, due diligence, development and construction. This firm's 30 years of unrivaled experience and superior knowledge of the southeast real estate market guarantees clients receive professional yet personalized service.
Cogan Realty has a proven track record in commercial real estate development, including office, multi-family, retail, restaurant, hotel and assisted living. Its vast network of relationships enables it to seize market opportunities and allows its clients to realize the highest return on their investment.
Major projects include:
$350 million mixed-use condominium and retail project planned for 25 acres at U.S. 41 and Stickney Point Road, south of Sarasota.
River Run Condominiums
A beautiful condominium community, located at 3600 Palm Valley Cir, Oviedo, FL, 32765.